SILVER SPRING, Md. – The U.S. Food and Drug Administration has approved Medtronic’s MiniMed 670G hybrid closed loop system, often referred to as an “artificial pancreas.” The device is intended to automatically monitor glucose and provide appropriate basal insulin doses for people with Type 1 diabetes ages 14 and older. “It’s the culmination of years of hard work,” said Alejandro Galindo, president of Intensive Insulin Management for the Diabetes Group at Medtronic. “The speed by which the FDA approved our PMA application submitted in June is truly unprecedented—just 104 days from submission to approval. That speaks volumes about the potential impact this innovative therapy can have on patients in the diabetes community.” Commercial release of the device will begin in the spring of 2017.
You are here: / / Artificial pancreas receives FDA approval